医薬品製造における世界のAI動向

製薬会社や開発・製造受託機関（CDMO）の製造、調達、購買担当幹部。戦略的計画、投資、提携の意思決定を行うために、人工知能の応用について深く理解しておく必要があります。

投資家、特にプライベートエクイティ投資家は、潜在的な投資対象を特定し評価するために、医薬品製造市場についてより深い理解を求めています。人工知能とデータサービスのベンダーは、この技術が医薬品製造セクターにどのような利益をもたらすかを理解する必要があります。

当レポートでは、医薬品製造における世界のAI動向について調査し、AIの概要とともに、新興製薬技術としてのAIの動向、現在の用途と将来の見通しなどについてまとめています。

目次

• エグゼクティブサマリー
• AIとは何か
• 新興製薬技術としてのAI
• 研究デザイン
• 医薬品製造におけるAI-現在の用途
• 医薬品製造におけるAI-将来の考慮事項
• 製造におけるAI-規制と倫理の課題
• 生成AIの質問
• より広範な製薬業界におけるAIの破壊
• 主要な調査結果の概要

付録

List of Figures

List of Figures

• Figure 1: AI as an Emerging Technology in the Past Four Years
• Figure 2: Looking to the Near Future: AI in the Next Two Years
• Figure 3: Headquarters location
• Figure 4: Seniority level and headquarters
• Figure 5: Primary business model and Practice Location
• Figure 6: AI Use in Pharmaceutical Manufacturing - By Company Type
• Figure 7: AI Use in Pharmaceutical Manufacturing - By Geography
• Figure 8: AI Use by Partners or Customers
• Figure 9: Types of AI - Pharmaceutical Manufacturing (I)
• Figure 10: Types of AI - Pharmaceutical Manufacturing (II)
• Figure 11: AI Implementation Pathway
• Figure 12: Areas of Pharma Manufacturing that AI Could Help With (I)
• Figure 13: Areas of Pharma Manufacturing that AI Could Help With (II)
• Figure 14: Challenges for Using AI in Pharmaceutical Manufacturing
• Figure 15: Pharma Manufacturing Regulation and AI
• Figure 16: The FDA's Stance: Is Risk-Based Regulation Applicable to AI in Drug Manufacturing?
• Figure 17: What Is Generative AI?
• Figure 18: Generative AI Use in Pharmaceutical Manufacturing
• Figure 19: Generative AI Use in Pharmaceutical Manufacturing (II)
• Figure 20: Generative AI Use in Pharmaceutical Manufacturing (III)
• Figure 21: AI - Technology That Will Disrupt the Pharma Industry
• Figure 22: AI - Hiring Trends
• Figure 23: Pharmaceutical Industry Prioritizes AI for Future Investments
• Figure 24: Annual company reports with AI mentions
• Figure 25: AI sentiment - annual reports
• Figure 26: AI in Manufacturing (1/3)
• Figure 27: AI in Manufacturing (2/3)
• Figure 28: AI in Manufacturing (3/3)

Abstract

This 63-page report gives important, expert insight you won't find in any other source. A total 28 figures throughout the report illustrate major points and trends. This report is required reading for -

• Manufacturing, sourcing, and procurement executives within pharma companies and contract development and manufacturing organizations (CDMOs), who must have a deep understanding of artificial intelligence's applications to make strategic planning, investment, and partnering decisions.
• Investors, especially private equity, seeking a deeper understanding of the pharmaceutical manufacturing market to identify and value potential investment targets.
• Artificial intelligence and data services vendors, who must understand how this technology can benefit the pharmaceutical manufacturing sector.

Reasons to Buy

• A detailed survey of pharmaceutical industry Key Opinion Leaders
• Clear explanations of artificial intelligence and related terminology
• Detailed analysis of current AI adoption in the pharmaceutical manufacturing sector
• Assessment of experts' attitudes to AI adoption in the near future in the pharmaceutical manufacturing sector
• Guide to practical, regulatory, and ethical challenges to increased AI use in pharmaceutical manufacturing
• A detailed breakdown of the US Food and Drug Administration's stance on AI
• Broader context of AI use in non-manufacturing sectors of pharma

Table of Contents

Table of Contents

• Executive Summary
• What is AI?
• AI as an Emerging Pharmaceutical Technology
• Study Design
• AI in Pharmaceutical Manufacturing - Current Use
• AI in Pharmaceutical Manufacturing - Future Considerations
• AI in Manufacturing - Regulatory and Ethical Challenges
• The Generative AI Question
• AI Disruption in the Broader Pharma Industry
• Summary of Key Findings

Appendix

• Contact Us